Bio-Thera Solutions Ltd.
http://www.bio-thera.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bio-Thera Solutions Ltd.
Idorsia’s Novel Hypertension Pill Among Eight New Drugs To Win EMA Nod
The European Medicines Agency believes Idorsia’s Jeraygo should be approved for use in the EU at two different doses rather than just the one approved by the US Food and Drug Administration last month.
Bio-Thera And Macter Partner On Bevacizumab
Bio-Thera Solutions has struck a deal with Macter International for rights to its BAT1706 biosimilar rival to Avastin (bevacizumab) in Pakistan and Afghanistan.
Bio-Thera Secures FDA Approval For Sandoz-Partnered Bevacizumab Biosimilar
Bio-Thera has received US Food and Drug Administration approval for its bevacizumab biosimilar, marking the second biosimilar drug researched, developed and manufactured by a Chinese pharmaceutical company to receive US approval.
Bio-Thera Delivers Positive Phase III Results For Stelara Biosimilar
Bio-Thera has announced positive Phase III results for its ustekinumab biosimilar candidate BAT2206, demonstrating that the product is highly similar to originator Stelara in patients with moderate to severe plaque psoriasis.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Biotech Biopharmaceutical Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice